• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjects

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Identification of proangiogenic plasmatic biomarkers in patients with advanced grade 1/2 pancreatic (pan) and gastrointestinal (gi) neuroendocrine tumors (NETs) treated with Lenvatinib: A subanalysis from the TALENT phase II clinical trial

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Authors
    Alvarez, A. G.
    Hernando, J.
    Jimenez-Valero, G.
    Martinez, A.
    Fazio, N.
    Lopez, C.
    Teule, A.
    Valle, Juan W
    Tafuto, S.
    Custodio, A.
    Casanovas, O.
    Capdevila, J.
    Show allShow less
    Affiliation
    Vall d'Hebron University Hospital, Barcelona, Spain
    Issue Date
    2022
    
    Metadata
    Show full item record
    Abstract
    Introduction:TALENT phase II trial provided evidence of the efficacy of Lenvatinib in patients with panNETs and giNETs. However, no predictive biomarker has been associated to antiangiogenic treatment benefit to date. Aim(s):Identify predictive biomarkers by evaluating a subset of proangiogenic molecules found in circulating plasma of patients included in the TALENT trial. Materials and methods:Plasma samples were obtained from 84 patients prior to the start of Lenvatinib. Quantitative determinations of VEGF-A, FGF2, FGF4, Ang2, IL8, PlGF, VEGF-C, VEGF-D and VEGFR2 were analysed by multiplex ELISA with a custom made Quantibody Array. Protein levels of each biomarker were correlated with PFS, OS and ORRin the different subgroups included in the trial. Results:In the whole population, a significant association of high-Ang2 and low-FGF2 plasma levels with higher ORR was observed. This association was independent of primary tumor origin, giNETs (p=0.003) and panNETs (p=0.024). In the panNET cohort (prior mTOR or multikinase inhibitors mandatory) 8 patients received Sunitinib previously. In this subgroup, Ang2 and VEGFR2 were significantly decreased compared to the rest of panNET patients (-73% p=0.022 and -62% p=0.042). Low levels of Ang-2 and VEGFR2 were associated to better ORR (p=0.029 and p=0.029) and PFS (log rank p=0.027 and p=0.007) in Sunitinib pre-treated patients. Prediction value capacity determined by ROC curve resulted in cutoffs for Ang2 and VEGFR2 being 415pg/ml and 1770pg/ml (p=0.021). Conclusion:High-Ang2 and low-FGF2 levels are associated to better response to lenvatinib in panNETs and giNETs and emerge as possible predictive factors of response to Lenvatinib. In Sunitinib-pretreated patients, Ang2 and VEGFR2 levels significantly predicted PFS and ORR in panNETs.
    Citation
    Alvarez AG, Hernando J, Jimenez-Valero G, Martinez A, Fazio N, Lopez C, et al. Identification of proangiogenic plasmatic biomarkers in patients with advanced grade 1/2 pancreatic (pan) and gastrointestinal (gi) neuroendocrine tumors (NETs) treated with Lenvatinib: A subanalysis from the TALENT phase II clinical trial. Journal of Neuroendocrinology. 2022;34:51.
    Journal
    Journal of Neuroendocrinology
    URI
    http://hdl.handle.net/10541/625241
    Type
    Meetings and Proceedings
    Language
    en
    Collections
    All Christie Publications

    entitlement

     
    DSpace software (copyright © 2002 - 2023)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.